AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01265342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone
Description: Beclomethasone nebulised suspension 400 micrograms twice a day for 10 days
Study NCT01265342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nebulised suspension twice a day for 10 days
Study NCT02628951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab injection for intravenous (I.V.) use, supplied in single-use 500-mg/50-mL vials containing 10 mg/mL of product in histidine buffer, administered as an I.V. infusion after dilution at 8 mg/kg every 2 weeks in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.
Study NCT02628951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 80 mg/m2 on Days 1, 8 and 15 of a 28-day cycle in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.
Study NCT02889757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acteylcysteine
Description: randomized into three arms
Study NCT02889757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acteylcysteine
Description: randomized into three arms
Study NCT00872482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nimotuzumab
Description: Nimotuzumab (200 mg fixed dose) will be administered by the intravenous route weekly during WBRT and following WBRT Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day.
Study NCT00872482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nimotuzumab
Description: Nimotuzumab (200 mg fixed dose) will be administered by the intravenous route weekly during WBRT and following WBRT Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day.
Study NCT02158286 — intervention group
Intervention type: OTHER
Intervention: Measuring emptying rate from the gastric tube
Study NCT03172663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pure tone audiometry
Description: for estimate the type and degree of hearing loss
Study NCT01875510 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish-oil emulsions
Description: Fish -oil emulsions:~Preterm infants will receive a fish-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and third day and after 3 gr/kg.
Study NCT01875510 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish-oil emulsions
Description: Fish -oil emulsions:~Preterm infants will receive a fish-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and third day and after 3 gr/kg.
Study NCT01875510 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: soybean-oil emulsion
Description: soybean-oil emulsion
Study NCT01875510 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: soybean-oil emulsion
Description: soybean-oil emulsion
Study NCT00659126 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3 Tesla Magnetic Resonance Imaging
Description: Undergo 3T MRI
Study NCT00659126 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DCE MRI
Study NCT00659126 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DSC MRI
Study NCT00659126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Given IV
Study NCT00659126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Given IV
Study NCT00659126 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Field Strength Magnetic Resonance Imaging
Description: Undergo 7T MRI
Study NCT00659126 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Susceptibility Weighted Imaging
Description: Undergo SWI
Study NCT03172663 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pure tone audiometry
Description: for estimate the type and degree of hearing loss
Study NCT03381209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: sugammadex given based on 3 measurements of body weights
Study NCT04202185 — intervention group
Intervention type: GENETIC
Intervention: Genetic analysis
Description: Research of mutation and identification of genetic panel as part of care
Study NCT03604497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: beacon alerts
Description: alerts via unidirectional communication from beacons to smartphones when smartphones are approaching pedestrian crossing at activated intersection
Study NCT03604497 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: no alerts retention
Description: no alerts will appear, but we will measure retention of behavior learned during the active intervention stage
Study NCT01460810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1000CsK Silicon Oil Tamponade
Description: Details covered in arm description
Study NCT01797757 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil enriched with EPA
Study NCT01797757 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MAG-EPA oil
Study NCT01797757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orlistat
Study NCT01239771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Tablet 1, 2, or 4 mg of TC-5213 will be given twice daily for 4 days and once on the 5th day.
Study NCT01239771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two subjects in each cohort will be given placebo.
Study NCT02982811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-ACT
Description: 3x 45 min training with i-ACT system (analytical and functional training) during 6 weeks, additional to therapy as usual (i.e. occupational therapy, physiotherapy, etc.)
Study NCT03830918 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT03830918 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Given IV
Study NCT03498547 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal block
Description: For the caudal block, sacral horns are palpated and sacral hiatus and epidural area will be determined at S4-S5 level through ulştrasonography. The 20 G adult caudal needle will then be placed to the caudal epidural space and 25 mL bupivacaine at a concentration of 0.5% will be applied in the prone Jack-Knife position with resistance loss.
Study NCT03498547 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: saddle block
Description: In the saddle block group hyperbaric bupivacaine at a dose of 7 mg will be given to the intrathecal space after a 25 G quincke spinal needle is inserted with ultrasonographyguidance between L4-L5 vertebral disc and clear cerebrospinal fluid is seen. The patient will be placed in sitting position for 5 minutes.
Study NCT02150213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI, CT or ultrasound was permitted if MRI was contraindicated
Description: MRI/CT/ultrasound of abdomen
Study NCT02150213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dexamethasone Supression Test
Description: Low dose of dexamethasone is administered in the evening; the next morning, a blood sample is collected to measure cortisol
Study NCT02150213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sonogram
Description: Sonogram of the uterus (females only)
Study NCT02150213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Uterine endometrial biopsy (females only)
Study NCT02150213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGG492
Description: No study-drug was administered in this study
Study NCT03379896 — intervention group
Intervention type: OTHER
Intervention: Collect peripheral blood sample
Description: Collect 20 ml heparinized blood from patients and controls strictly abiding by the principle of aseptic manipulation after informed consent.
Study NCT01125293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study NCT01125293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT01125293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study NCT04108819 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Subjects will undergo ketogenic diet at a 2.5:1 (fat: carb + protein) ratio for a 2-week period.
Study NCT03830918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given PO
Study NCT03830918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03830918 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03830918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03830918 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03830918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT06462859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory Integration Therapy Group
Description: The experimental group received sensory integration therapy in addition to the NDT program. The NDT program is customized for each child, featuring a unique blend of static and dynamic balance exercises, coordination exercises, mobility exercises, and strength training exercises. Participants attended 45-minute NDT and sensory integration sessions three times a week for 8 weeks. Sensory integration therapy, visual perception activities (block design, shape recognition in pictures, puzzles, matching geometric shapes and letters, numbers and classification exercises), body awareness activities (showing body parts, drawing life-size drawings, turning left and right, recognizing body parts by touching ), tactile perception exercises (feeling and touching various textures and shapes) and visual-motor coordination training (eye tracking exercises, activities with moving objects and panel activities).
Study NCT06462859 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neurodevelopmental Treatment Group
Description: The NDT program is customized for each child, featuring a mix of static and dynamic balance exercises, coordination exercises, mobility exercises, and strength training exercises. He attended 45-minute NDT sessions three times a week for 8 weeks. There is no treatment or medication other than NDT.
Study NCT06462859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental Treatment Group
Description: The NDT program is customized for each child, featuring a mix of static and dynamic balance exercises, coordination exercises, mobility exercises, and strength training exercises. He attended 45-minute NDT sessions three times a week for 8 weeks. There is no treatment or medication other than NDT.
Study NCT04018586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVACEN 100
Description: AVACEN 100 pulls a -30mmHg vacuum around hand from wrist down and applies heat (108 farenheit) to the palm and will be applied for 30 minutes
Study NCT04018586 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AVACEN 100 Heat Only
Description: AVACEN 100 applies heat (108 Fahrenheit) to the palm and will be applied for 30 minutes
Study NCT04018586 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AVACEN Sham
Description: AVACEN 100 neither heats nor pulls a vacuum to hand
Study NCT03290170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measured Resection
Description: Bony landmarks are used to set femoral component rotation.
Study NCT03290170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gap Balancing
Description: Relies on ligament releases prior to bone cuts.
Study NCT01578538 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inguinal hernia repair
Description: strangulated hernias will be repaired surgically
Study NCT01229514 — intervention group
Intervention type: OTHER
Intervention: fMRI
Description: fMRI and a response inhibition task to examine activation patterns in the prefrontal cortex and caudate nucleus
Study NCT04344262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atracurium Besylate regular dose
Description: Intubating dose of muscle relaxant will be atracurium 0.5 mg/kg~Maintenance doses of muscle relaxant will be given throughout the intraoperative period~to maintain the Train-of-four values continuously less than 2
Study NCT04344262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atracurium Besylate minial dose
Description: atracurium boluses of muscle relaxant given only upon complain of the surgeon and after a bolus dose of propofol 0.5 mg/kg. When required, 20% of the initial dose of muscle relaxant will be provided as a bolus to achieve this goal
Study NCT02099487 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: hypofractionated IMRT
Study NCT00907972 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3
Study NCT00907972 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03514004 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICT-based intervention
Description: The ICT-based intervention, known as Project Clan, includes both a web-platform and a mobile application. Project Clan includes both informational and interactive features, ranging from traditional suicide prevention strategies (e.g., a chat with a psychologist, emergency phone hotline, and tips) that seek to reduce barriers to access quality, useful, and evidence-based information and rapid professional assistance, to components designed to increase interactions between participants and promote a sense of belonging and connection with the other Clan members.
Study NCT00511849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin + SU011248 (sunitinib) + paclitaxel
Description: AUC of 6 mg\*min/mL administered as a 30-minute infusion, every 21 days for 4 cycles or until progression/unacceptable toxicity. 25 mg, 37.5 mg, or 50 mg (depending on the dose level assigned) orally taken every day or for 2 weeks and 1 week off without for 4 cycles or until progression/unacceptable toxicity. 175 mg/m2, 200 mg/m2, or 225 mg/m2 (depending on the dose level assigned), administered as a 3-hour infusion every 21 days for 4 cycles or until progression/unacceptable toxicity.
Study NCT04048538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Precare
Description: an innovative patient education platform using animated videos created by using up-to-date evidence-based informaiton
Study NCT04048538 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual standard of care
Description: individuals will receive treatment as per the usual standard of care
Study NCT00378976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valacyclovir
Description: 500 mg twice-daily oral
Study NCT00378976 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: twice daily as per experimental drug
Study NCT03594864 — intervention group
Intervention type: PROCEDURE
Intervention: Liver transplantation with hyper-reduced grafts
Description: Live donor liver transplantation using non-anatomical in-situ ultrasound-guided reduction of left lateral segments with preparation of a graft that is larger than a monosegment, but smaller than Segments 2 and 3.
Study NCT00444964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nutropin AQ
Description: 0.0125 mg/kg/day
Study NCT01142479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chinese herbal medicine decoction
Description: 100 ml /Qd for 6 weeks(42 days)
Study NCT01142479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine decoction
Description: 100 ml /Qd for 6 weeks(42 days)
Study NCT01052181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Oral Cholecalciferol sachets 120,000 IU monthly for 1 year
Study NCT01052181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 sachets monthly for an year
Study NCT01455415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: 150 - 300 mg/day in divided dose (3 time a day) for 6 weeks
Study NCT01455415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo 3 time a day
Study NCT00033228 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MKC1106-MT
Description: Cancer Vaccine, Immunotherapy, 500 ug
Study NCT00033228 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MKC1106-MT
Description: Cancer Vaccine, Immunotherapy, 1000 ug
Study NCT01411423 — intervention group
Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Patients who have received Nexavar for unresectable or advanced RCC.
Study NCT02994745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan, Atorvastatin
Study NCT02994745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan, Atorvastatin
Study NCT00033228 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MKC1106-MT
Description: Cancer Vaccine, Immunotherapy, 1500 ug
Study NCT02427100 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet/Physical Activity
Description: Diet/Physical Activity Intervention
Study NCT03509844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Three established psychotherapeutic models for treatment of complex posttraumatic stress disorders are compared in a residential care setting. Combination of group and individual sessions.
Study NCT00407550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine HCL
Description: 1250 mg/m\^2 administered through 250 cc NS (normal saline) IV (intravenous) infusion over 30 minutes at days 1 \& 8 of each cycle (21 days) x6 cycles.
Study NCT00407550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: 500 mg/m\^2 administered through 100 mL NS IV infusion over 10 minutes at day 1 of each cycle.
Study NCT00407550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine HCL
Description: 1500 mg/m\^2 administered through 250 cc NS IV infusion over 30 minutes at days 1 of each cycle (14 days) x9 cycles.
Study NCT02796833 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SMOFlipid20%
Study NCT04594629 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Nitroglycerin
Description: Patients of nitroglycerine group received nebulized nitro glycerine (a vial contains 50 mg nitroclycerine ), its starting concentration was 200 mcg/ml with nitro glycerine was delivered at 2.5-5 mcg/kg/min (5 mg, 1 mg/ml) over 10 minutes by ultrasonic nebuliser connected to the inspiratory limb of the breathing circuit
Study NCT03963037 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: Draw venous blood for baseline blood parameters and plasma samples for lipoprotein fractionation.
Study NCT04594629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PGI2
Description: Patients of PGI2 group received nebulized PGI2 (epoprostenol), 20000 ng/ml (Flolan; Glaxo Wellcome Inc, Research Triangle Park, NC) (60 ml syringe of PGI2 with concentration 20000 ng/ml was attached to an intravenous pump which delivers a titrating rate of 8 ml/h to the nebulizer compartment (MiniHEART nebulizer; Westmed, Tucson, Ariz) fixed to the inspiratory limb of the breathing circuit or to the face mask with venturi accessory for sprinkling. The nebulizer was filled with 15 ml PGI2 with nebulized oxygen flow rate 3 litres
Study NCT06109519 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant supported overdenture
Description: patients would be delivered mandibular implant overdenture using conventional locator and Locator RTX attachments
Study NCT00917566 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq
Description: intubation with airtraq
Study NCT00917566 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintoch
Description: use Macintoch laryngoscope for intubation
Study NCT02544399 — intervention group
Intervention type: OTHER
Intervention: 3D CT scan
Description: Measure of bone micro-architecture by 3D micro-tomography